Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2 Thoracic 1 Sarcoma 1 Head & Neck 1 Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780 Fluorouracil 638 Capecitabine 575 Gemcitabine 478 Leucovorin 459 Bevacizumab 445 Irinotecan 444 Cisplatin 338 Radiotherapy 283 Cetuximab 252 Paclitaxel 180 S 1 (combination) 176 pembrolizumab 173 Docetaxel 156 Drug Therapy 147 Nivolumab 146 sintilimab 143 tislelizumab 131 apatinib 131 130-nm albumin-bound paclitaxel 128 Folfox protocol 121 durvalumab 119 Albumin-Bound Paclitaxel 117 camrelizumab 107 lenvatinib 106 Panitumumab 106 regorafenib 102 Surgical Procedures, Operative 102 Sorafenib 99 Radiation 88

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tirapazamine × Gastrointestinal × Clear all

NCT03145558 2024-11-22

TATE

Teclison Ltd.

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡